Payment overview · 2025
General Payments
$1,582.92
87 reported records · 26 companies
Healthcare provider profile · identity verified
Anu Chaudhry, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · RAHWAY, NJ · NPI 1295709061
Verified facts
What the public records show
CMS Open Payments records show Anu Chaudhry, MD received $1,582.92 in general payments during 2025 across 87 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Velphoro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Fresenius USA Marketing, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VELPHORO as an associated drug or biological on 8763 records involving 2642 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Velphoro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $253.42 | 16.0% | 12 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $222.08 | 14.0% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $122.28 | 7.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $87.40 | 5.5% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $71.34 | 4.5% | 3 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.90 | 4.5% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $70.17 | 4.4% | 4 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $67.59 | 4.3% | 4 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $63.63 | 4.0% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.88 | 3.9% | 3 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $52.69 | 3.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.26 | 3.1% | 3 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $43.98 | 2.8% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$38.91 | 2.5% | 2 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $38.48 | 2.4% | 2 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $37.34 | 2.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.92 | 2.1% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $30.92 | 1.9% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $30.03 | 1.9% | 2 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $29.32 | 1.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.59 | 1.4% | 1 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.32 | 1.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.59 | 1.2% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.30 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.92 | 0.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.66 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,582.92 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $222.08 | 13 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $122.28 | 7 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $120.09 | 10 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $71.34 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $67.59 | 4 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $63.63 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $61.88 | 3 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $52.69 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $51.65 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $50.67 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.26 | 3 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $43.98 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $38.91 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $38.48 | 2 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $37.34 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.75 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $34.85 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.92 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $30.03 | 2 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.59 | 1 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| Vanrafia Normalized: vanrafia |
Drug | Novartis Pharmaceuticals Corporation | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| VOYXACT Normalized: voyxact |
Drug | Otsuka America Pharmaceutical, Inc. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| GATTEX Normalized: gattex |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 111 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 67 | exact normalized | Medicare Part D |
| VELPHORO velphoro |
2025 | Velphoro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
111 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
36 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Fresenius USA Marketing, Inc. Exact reporting entity; no affiliate inference |
2025 | VELPHORO open payments reported associated product |
CMS Open Payments — General Payments 8763 supporting records · 2642 recipient NPIs · example record 1244803773 |
Velphoro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 474 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 333 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 253 | 54 |
| Furosemide | Furosemide | 219 | 49 |
| Eliquis | Apixaban | 210 | 40 |
| Carvedilol | Carvedilol | 208 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 52 |
| Losartan Potassium | Losartan Potassium | 193 | 46 |
| Metoprolol Succinate | Metoprolol Succinate | 189 | 69 |
| Gabapentin | Gabapentin | 187 | 49 |
| Sertraline Hcl | Sertraline Hcl | 187 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 36 |
| Enoxaparin Sodium | Enoxaparin Sodium | 161 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 161 | 31 |
| Metformin Hcl | Metformin Hcl | 160 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 153 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 31 |
| Donepezil Hcl | Donepezil Hcl | 145 | 19 |
| Prosol | Parenteral Amino Acid 20% No.1 | 117 | suppressed |
| Lisinopril | Lisinopril | 112 | 31 |
| Farxiga | Dapagliflozin Propanediol | 111 | 31 |
| Nifedipine Er | Nifedipine | 110 | 32 |
| Ezetimibe | Ezetimibe | 103 | 22 |
| Torsemide | Torsemide | 96 | 18 |
| Simvastatin | Simvastatin | 88 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 83 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 35 |
| Allopurinol | Allopurinol | 75 | 20 |
| Colchicine | Colchicine | 75 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 75 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 25 |
| Montelukast Sodium | Montelukast Sodium | 72 | 23 |
| Ozempic | Semaglutide | 67 | 14 |
| Januvia | Sitagliptin Phosphate | 66 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 63 | 15 |
| Famotidine | Famotidine | 60 | 22 |
| Sevelamer Carbonate | Sevelamer Carbonate | 59 | 17 |
| Prednisone | Prednisone | 56 | 28 |
| Omeprazole | Omeprazole | 55 | 18 |
| Primidone | Primidone | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 49 | suppressed |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 46 | 11 |
| Trazodone Hcl | Trazodone Hcl | 46 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Latanoprost | Latanoprost | 44 | suppressed |
| Mirtazapine | Mirtazapine | 42 | 11 |
| Entresto | Sacubitril/Valsartan | 41 | suppressed |
| Glimepiride | Glimepiride | 40 | 14 |
| Valsartan | Valsartan | 40 | 11 |
| Midodrine Hcl | Midodrine Hcl | 39 | 14 |
| Tramadol Hcl | Tramadol Hcl | 39 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Glipizide | Glipizide | 37 | 13 |
| Enalapril Maleate | Enalapril Maleate | 36 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 36 | 16 |
| Xarelto | Rivaroxaban | 36 | suppressed |
| Bumetanide | Bumetanide | 35 | 11 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 13 |
| Calcium Acetate | Calcium Acetate | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 11 |
| Olanzapine | Olanzapine | 31 | suppressed |
| Azithromycin | Azithromycin | 29 | 26 |
| Heparin Sodium | Heparin Sodium,porcine | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Insulin Lispro | Insulin Lispro | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Clinisol | Parenteral Amino Acid 15% No.5 | 22 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 16 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 16 |
| Folic Acid | Folic Acid | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Adapalene | Adapalene | 11 | suppressed |
| Epogen | Epoetin Alfa | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Velphoro | Sucroferric Oxyhydroxide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,582.92 · 87 records | Otsuka America Pharmaceutical, Inc. | ACTHAR, AREXVY, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Fabhalta, GATTEX, Hillrom - Carnation Ambulatory Monitor, IBSRELA, JARDIANCE, JYNARQUE, Kerendia, LEQVIO, LUPKYNIS, MOUNJARO, Omnipod, Ozempic, PURIFIED CORTROPHIN GEL, RAYALDEE, Rybelsus, SHINGRIX, SYMPLICITY G3, Saxenda, TARPEYO, TAVNEOS, ULTOMIRIS, VELPHORO, VOYXACT, Vafseo, Vanrafia, Veltassa, Wegovy, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error